BidaskClub Downgrades Flexion Therapeutics (NASDAQ:FLXN) to Sell

BidaskClub cut shares of Flexion Therapeutics (NASDAQ:FLXN) from a hold rating to a sell rating in a research note issued to investors on Tuesday, BidAskClub reports.

Several other brokerages have also issued reports on FLXN. Wells Fargo & Co reiterated a buy rating on shares of Flexion Therapeutics in a research report on Wednesday, April 10th. Northland Securities reiterated a buy rating and issued a $55.00 target price on shares of Heron Therapeutics in a research report on Thursday, May 9th. Zacks Investment Research upgraded shares of Garrett Motion from a sell rating to a hold rating in a research report on Friday, May 10th. Benchmark reiterated a buy rating on shares of Gray Television in a research report on Thursday, May 9th. Finally, Raymond James reiterated a buy rating on shares of Flexion Therapeutics in a research report on Thursday, March 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Flexion Therapeutics presently has a consensus rating of Buy and a consensus price target of $23.71.

Shares of NASDAQ:FLXN opened at $10.65 on Tuesday. Flexion Therapeutics has a 52-week low of $9.65 and a 52-week high of $27.84. The stock has a fifty day moving average of $11.56. The stock has a market capitalization of $414.09 million, a price-to-earnings ratio of -2.37 and a beta of 1.41. The company has a debt-to-equity ratio of 2.10, a current ratio of 6.32 and a quick ratio of 6.06.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.04. Flexion Therapeutics had a negative net margin of 549.07% and a negative return on equity of 131.94%. The company had revenue of $10.56 million during the quarter, compared to analyst estimates of $11.10 million. Equities analysts predict that Flexion Therapeutics will post -4.07 earnings per share for the current fiscal year.

In other news, insider Michael D. Clayman acquired 4,012 shares of the stock in a transaction dated Friday, May 10th. The stock was purchased at an average cost of $12.48 per share, with a total value of $50,069.76. Following the completion of the purchase, the insider now owns 74,868 shares in the company, valued at approximately $934,352.64. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO David Arkowitz acquired 4,000 shares of the stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $11.99 per share, with a total value of $47,960.00. Following the completion of the purchase, the chief financial officer now owns 86,924 shares of the company’s stock, valued at approximately $1,042,218.76. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 18,512 shares of company stock valued at $226,775. Company insiders own 16.01% of the company’s stock.

Several large investors have recently modified their holdings of the company. Pictet Asset Management Ltd. raised its stake in shares of Flexion Therapeutics by 0.6% during the first quarter. Pictet Asset Management Ltd. now owns 1,432,159 shares of the specialty pharmaceutical company’s stock valued at $17,873,000 after acquiring an additional 8,139 shares during the last quarter. Wasatch Advisors Inc. raised its stake in shares of Flexion Therapeutics by 7.8% during the first quarter. Wasatch Advisors Inc. now owns 1,016,137 shares of the specialty pharmaceutical company’s stock valued at $12,681,000 after acquiring an additional 73,751 shares during the last quarter. Gagnon Securities LLC raised its stake in shares of Flexion Therapeutics by 171.2% during the first quarter. Gagnon Securities LLC now owns 688,271 shares of the specialty pharmaceutical company’s stock valued at $8,590,000 after acquiring an additional 434,448 shares during the last quarter. Gagnon Advisors LLC raised its stake in shares of Flexion Therapeutics by 89.6% during the first quarter. Gagnon Advisors LLC now owns 401,648 shares of the specialty pharmaceutical company’s stock valued at $5,013,000 after acquiring an additional 189,860 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Flexion Therapeutics by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 384,433 shares of the specialty pharmaceutical company’s stock valued at $4,351,000 after acquiring an additional 7,814 shares during the last quarter. 89.88% of the stock is owned by hedge funds and other institutional investors.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Read More: What is the CBOE Russell 2000® Volatility Index?

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.